Clinical responses, such as decreases in the Birmingham Vasculitis Activity Score (BVAS), improvements in the estimated glomerular filtration rate (eGFR), and decreases in urinary albumin-to-creatinine ratios, have been documented in some of these studies, especially the studies by Jayne et al. [12, 16, 17, 29] and Geetha et al. [31] Improvement in renal parameters suggests avacopan’s therapeutic benefit and its potential to prevent long-term organ damage, a key goal in AAV management. The gene discussed is ALB; the disease is vasculitis.